Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
Thiazole-based inhibitors of scavenger receptor BI
US9951055B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9951055-B2 |
| Application number | US-201314436626-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 21, 2013 |
| Priority date | Oct 19, 2012 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the formula: or a salt or solvate thereof. 2. A compound of the formula: or a salt or solvate thereof. 3. A method of inhibiting Scavenger receptor class B, type I (SR-BI) lipid transport activity comprising exposing said receptor to a compound of the formula or a salt or solvate thereof. 4. A method of inhibiting Scavenger receptor class B, type I (SR-BI) lipid transport activity comprising exposing said receptor to a compound of the formula: or a salt or solvate thereof. 5. The method of claim 3 or 4 , wherein said lipid transport activity is determined by measuring the binding of 125 I-HDL or Alexa-labeled HDL to cells. 6. The method of claim 3 or 4 , wherein said method comprises increasing the strength of binding of high-density lipoprotein (HDL) to cells. 7. The method of claim 3 or 4 , wherein said method comprises inhibiting SR-BI transport of cholesteryl ester or other lipids from high-density lipoprotein (HDL) into cells expressing SR-BI. 8. The method of claim 3 or 4 , wherein said method comprises inhibiting transport of cholesterol or other lipids from cells expressing SR-BI into high-density lipoprotein (HDL). 9. A method of treating a hepatitis C viral infection, comprising administering to a subject in need thereof an effective amount of a compound of the formula: or a salt or solvate thereof. 10. A method of treating a hepatitis C viral infection, comprising administering to a subject in need thereof an effective amount of a compound of the formula: or a salt or solvate thereof.
Assignees
Inventors
Classifications
linked by a chain containing hetero atoms as chain links · CPC title
Acylated amino or imino radicals · CPC title
containing three or more hetero rings · CPC title
the oxygen-containing ring being five-membered · CPC title
Antivirals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9951055B2 cover?
- This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
- Who is the assignee on this patent?
- Broad Inst Inc, Massachusetts Inst Technology
- What technology area does this patent fall under?
- Primary CPC classification C07D417/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).